Tarcocimab Biosimilar – Anti-VEGFA mAb – Research Grade from ProteoGenix; catalogue PX-TA1780; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Tarcocimab Biosimilar, also known as Anti-VEGFA mAb, is a monoclonal antibody that specifically targets the vascular endothelial growth factor A (VEGFA). This biosimilar is a research-grade version of the original Tarcocimab, which is a therapeutic antibody used in the treatment of various diseases. In this article, we will discuss the structure, activity, and potential applications of Tarcocimab Biosimilar.
Tarcocimab Biosimilar is a humanized monoclonal antibody, meaning it is derived from both human and non-human sources. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab region is responsible for binding to the VEGFA molecule, while the Fc region plays a role in immune effector functions.
The main function of Tarcocimab Biosimilar is to inhibit the activity of VEGFA. VEGFA is a key factor in the formation of new blood vessels, a process known as angiogenesis. In certain diseases, such as cancer and age-related macular degeneration, VEGFA is overexpressed, leading to excessive angiogenesis. This can result in tumor growth and abnormal blood vessel formation in the eye, leading to vision loss. By binding to VEGFA, Tarcocimab Biosimilar prevents it from interacting with its receptors, thereby reducing angiogenesis and inhibiting disease progression.
Tarcocimab Biosimilar also has immunomodulatory effects. It can bind to Fc receptors on immune cells, such as natural killer cells and macrophages, and activate them to destroy cancer cells. This mechanism, known as antibody-dependent cellular cytotoxicity (ADCC), enhances the therapeutic effect of Tarcocimab Biosimilar in cancer treatment.
Tarcocimab Biosimilar has potential applications in various diseases, particularly those involving excessive angiogenesis. In oncology, it can be used as a monotherapy or in combination with other anticancer agents to treat solid tumors, such as breast, lung, and colon cancer. It has shown promising results in clinical trials, with some patients achieving complete remission.
In ophthalmology, Tarcocimab Biosimilar can be used to treat age-related macular degeneration, a leading cause of blindness in the elderly. By inhibiting VEGFA, it can prevent the growth of abnormal blood vessels in the retina, preserving vision.
Tarcocimab Biosimilar may also have potential in other diseases, such as diabetic retinopathy, psoriasis, and rheumatoid arthritis, where angiogenesis plays a role in disease progression. Further research is needed to fully explore its therapeutic potential in these conditions.
Tarcocimab Biosimilar is a promising research-grade monoclonal antibody that specifically targets VEGFA. Its structure and activity make it an effective inhibitor of angiogenesis, with potential applications in various diseases. As more studies are conducted, Tarcocimab Biosimilar may become a valuable therapeutic option for patients in need of VEGFA inhibition.
ProteoGenix catalogue number PX-TA1780. For research use only.
Target: Tarcocimab Biosimilar – Anti-VEGFA mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Tarcocimab Biosimilar – Anti-VEGFA mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
